DermatologyNews.net

Dermatology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

New six-and-a-half-year data from CheckMate -067, a randomized, double-blind, phase 3 clinical trial, demonstrating durable improvement in survival with first-line Nivolumab ( Opdivo ) plus Ipilimumab ...


Klisyri ( Tirbanibulin ) is a novel microtubule inhibitor, indicated for the topical treatment of actinic keratosis ( AK ) and it acts through a selective antiproliferative mechanism of action. The ...


Results from two pivotal phase 3 trials evaluating Deucravacitinib, an oral, selective tyrosine kinase 2 ( TYK2 ) inhibitor, for the treatment of patients with moderate to severe plaque psoriasis, wer ...


Topical Minoxidil is the only FDA–approved drug for treatment of female-pattern hair loss ( FPHL ). Premature discontinuation of treatment commonly occurs because of the lack of perceived efficacy, ...


Topical steroids have been previously associated with potential for hyperglycemia and glucosuria, and thought to have a relatively safe side effect profile. In prolonged use, there is the potential ...


Ixekizumab ( Taltz ) met the primary and all major secondary endpoints up to week 12 in the phase 4 IXORA-R study, which evaluated the efficacy and safety of Ixekizumab versus Guselkumab ( Tremfya ) i ...


Dupilumab ( Dupixent ) is the first biologic available to treat atopic dermatitis. Its effectiveness and safety were demonstrated in clinical trials. The aim of study was to assess the effectivenes ...


In the U.S.A., an Investigator's Global Assessment ( IGA ) score of less than or equal to 1 ( clear or almost clear skin ) has been the standard measure in regulatory outcomes for registration clinica ...


Epidermal growth factor receptor inhibitors ( EGFRi ), EGFR tyrosine kinase inhibitors ( TKI ) and anti‐EGFR antibodies commonly develop skin toxicities including acneiform eruption. However, precise ...


ECLIPSE trial has demonstrated that Guselkumab ( Tremfya ) was superior to Secukinumab ( Cosentyx ) in treating adults with moderate to severe plaque psoriasis for the primary endpoint assessed at wee ...


Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, is approved for the treatment of moderate-to-severe psoriasis. An overview has analyzed the efficacy o ...


Nail psoriasis is associated with functional impairment, pain and reduced quality of life. The aim of a study was to demonstrate the superiority of Secukinumab ( Cosentyx ) versus placebo in cleari ...


Photodynamic therapy ( PDT ) is an attractive therapy for nonmelanoma skin cancers and actinic keratoses ( AKs ). Daylight-mediated photodynamic therapy is a simple and tolerable treatment procedure ...


Hidradenoma usually presents as a solitary, slow-growing, and solid or cystic nodular lesion, which arises in various anatomical sites. Its diagnosis is occasionally difficult because the tumor shares ...


Bristol-Myers Squibb pioneered the use of immune checkpoint inhibitors for the adjuvant treatment of melanoma, beginning with Yervoy. Five-year overall survival data from the phase 3 CA184-029 trial ...